other material
confidence high
sentiment positive
materiality 0.90
Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
Janux Therapeutics, Inc.
- 100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
- 75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.
- 50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.
- CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.
- Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients.